tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Apr 16;9(4):395.
doi: 10.3390/vaccines9040395.
Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
Lisha Zha[SUP] 1 [/SUP], Xinyue Chang[SUP] 2 3 [/SUP], Hongxin Zhao[SUP] 4 [/SUP], Mona O Mohsen[SUP] 2 3 5 [/SUP], Liang Hong[SUP] 1 [/SUP], Yuhang Zhou[SUP] 6 [/SUP], Hongquan Chen[SUP] 1 [/SUP], Xuelan Liu[SUP] 1 2 [/SUP], Jie Zhang[SUP] 6 [/SUP], Dong Li[SUP] 7 [/SUP], Ke Wu[SUP] 8 [/SUP], Byron Martina[SUP] 9 [/SUP], Junfeng Wang[SUP] 4 [/SUP], Monique Vogel[SUP] 2 3 [/SUP], Martin F Bachmann[SUP] 1 2 10 [/SUP]
Affiliations
Abstract
The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here, we demonstrated that the recombinantly expressed receptor-binding domain (RBD) of the spike protein can be coupled to immunologically optimized virus-like particles derived from cucumber mosaic virus (CuMV[SUB]TT[/SUB]). The RBD displayed CuMV[SUB]TT[/SUB] bound to ACE2, the viral receptor, demonstrating proper folding of RBD. Furthermore, a highly repetitive display of the RBD on CuMV[SUB]TT[/SUB] resulted in a vaccine candidate that induced high levels of specific antibodies in mice, which were able to block binding of the spike protein to ACE2 and potently neutralize SARS-CoV-2 virus in vitro.
Keywords: BLI; COVID-19; CuMVTT?RBD; vaccine; virus-like particle.
. 2021 Apr 16;9(4):395.
doi: 10.3390/vaccines9040395.
Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
Lisha Zha[SUP] 1 [/SUP], Xinyue Chang[SUP] 2 3 [/SUP], Hongxin Zhao[SUP] 4 [/SUP], Mona O Mohsen[SUP] 2 3 5 [/SUP], Liang Hong[SUP] 1 [/SUP], Yuhang Zhou[SUP] 6 [/SUP], Hongquan Chen[SUP] 1 [/SUP], Xuelan Liu[SUP] 1 2 [/SUP], Jie Zhang[SUP] 6 [/SUP], Dong Li[SUP] 7 [/SUP], Ke Wu[SUP] 8 [/SUP], Byron Martina[SUP] 9 [/SUP], Junfeng Wang[SUP] 4 [/SUP], Monique Vogel[SUP] 2 3 [/SUP], Martin F Bachmann[SUP] 1 2 10 [/SUP]
Affiliations
- PMID: 33923573
- DOI: 10.3390/vaccines9040395
Abstract
The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here, we demonstrated that the recombinantly expressed receptor-binding domain (RBD) of the spike protein can be coupled to immunologically optimized virus-like particles derived from cucumber mosaic virus (CuMV[SUB]TT[/SUB]). The RBD displayed CuMV[SUB]TT[/SUB] bound to ACE2, the viral receptor, demonstrating proper folding of RBD. Furthermore, a highly repetitive display of the RBD on CuMV[SUB]TT[/SUB] resulted in a vaccine candidate that induced high levels of specific antibodies in mice, which were able to block binding of the spike protein to ACE2 and potently neutralize SARS-CoV-2 virus in vitro.
Keywords: BLI; COVID-19; CuMVTT?RBD; vaccine; virus-like particle.